$139.88 2.4%
TMDX Stock Price vs. AI Score
Data gathered: September 7

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.


TransMedics Group
Price $139.88
Target Price Sign up
Volume 1,490,000
Market Cap $5.03B
Year Range $70.86 - $176.11
Dividend Yield 0%
PE Ratio 3584.62
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '24114M45M69M12M16M0.350
Q1 '2497M37M60M12M16M0.350
Q4 '2381M33M48M4M6.3M0.120
Q3 '2366M26M41M-25M-23M-0.780
Q2 '2352M16M37M-1M1.5M-0.030

Insider Transactions View All

Khayal Tamer I filed to sell 20,943 shares at $164.7.
September 5 '24
Khayal Tamer I filed to sell 20,975 shares at $163.1.
September 5 '24
Khayal Tamer I filed to sell 20,843 shares at $165.9.
September 5 '24
Khayal Tamer I filed to sell 22,151 shares at $159.
September 5 '24
Khayal Tamer I filed to sell 21,755 shares at $160.7.
September 5 '24

What is the Market Cap of TransMedics Group?

The Market Cap of TransMedics Group is $5.03B.

What is TransMedics Group's PE Ratio?

As of today, TransMedics Group's PE (Price to Earnings) ratio is 3584.62.

What is the current stock price of TransMedics Group?

Currently, the price of one share of TransMedics Group stock is $139.88.

How can I analyze the TMDX stock price chart for investment decisions?

The TMDX stock price chart above provides a comprehensive visual representation of TransMedics Group's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling TransMedics Group shares. Our platform offers an up-to-date TMDX stock price chart, along with technical data analysis and alternative data insights.

Does TMDX offer dividends to its shareholders?

As of our latest update, TransMedics Group (TMDX) does not offer dividends to its shareholders. Investors interested in TransMedics Group should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of TransMedics Group?

Some of the similar stocks of TransMedics Group are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.